Abstract
Modern immunotherapy with checkpoint inhibitors has changed clinical practice of adult patients with advanced cancer. Blockade of CTLA-4 and PD-1 pathways have shown survival benefits in different diseases. In children, combination of surgery, radiotherapy and chemotherapy have improved survival rates of solid tumors. However, the outcomes for subsets of patients such as those with high-grade, refractory, or metastatic disease remain extremely poor. Currently, the treatment of these patients is almost exclusively based on standard chemotherapy. The significant proportion of pediatric cancers with high number of mutations and subsequent high expression of neoantigens, together with the potential prognostic role of the immunosuppressive checkpoint molecules (CTLA-4, PD-L1) can represent a promising rationale that support the use of checkpoint inhibitors. We made a revision about emerging data regarding safety and activity of checkpoint inhibitors in children with solid tumors.
Similar content being viewed by others
Abbreviations
- CTLA4:
-
Cytotoxic T lymphocyte antigen 4
- PD1:
-
Programmed cell death protein 1
- PD-L1:
-
PD-1 ligand 1
- NSCLC:
-
Lung cancer
- RCC:
-
Renal clear cell carcinoma
- HL:
-
Hodgkin’s lymphoma
- irAE:
-
Immune-related adverse events
- HSCT:
-
Hematologic stem cell transplantation
- GVHD:
-
Graft-versus-host disease
- bMMRD:
-
Biallelic mismatch repair deficiency
- CNS:
-
Central nervous system
References
Pandolfi F, Cianci R, Lolli S et al (2008) Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol 21:493–500
Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174
Stewart TJ, Smyth MJ (2011) Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 30:125–140
Ribas A (2015) Releasing the brakes on cancer immunotherapy. N Engl J Med 373:1490–1492
Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34
Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for check-point inhibitor-based immunotherapy. Lancet Oncol 17(12):542–551
Campbell BB, Angelini P, Fabrizio D et al (2017) Large scale tumor mutational burden analysis of pediatric tumors provides a diagnostic tool for germline predisposition and reveals novel candidates for immune checkpoint inhibition. Neuro-Oncology 19(S4):30
Hingorani P, Maas ML, Gustafson MP et al (2015) Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients. J Immunother Cancer 3:35
Chowdhury F, Dunn S, Mitchell S et al (2015) PD-L1 and CD8+ PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. Oncoimmunology 4:e1029701
Kim C, Kim EK, Jung H et al (2016) Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 16:434
Majzner RG, Simon JS, Grosso JF et al (2015) Assessment of PD-L1 expression and tumor-associated lymphocytes in pediatric cancer tissues. Cancer Res 75:249
Routh JC, Ashley RA, Sebo TJ et al (2008) B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol 179:1954–1959
Aoki T, Hino M, Koh K et al (2016) Low frequency of programmed death ligand 1 expression in pediatric cancers. Pediatr Blood Cancer 63:1461–1464
Merchant MS, Wright M, Baird K et al (2016) Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res 22:1364–1370
Bajčiová V (2015) Therapeutic effect and tolerance of ipilimumab in metastatic malignant melanoma in children—a case report. Klin Onkol 28(Suppl 4):115–120
Shad AT, Huo JS, Darcy C et al (2017) Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report. Pediatr Blood Cancer 64(3):e26257
Foran AE, Nadel HR, Lee AF, Savage KJ, Deyell RJ (2016) Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma. J Pediatr Hematol Oncol 39(5):e263–e266
Bouffet E, Larouche V, Campbell BB et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206–2211
Blumenthal DT, Yalon M, Vainer GW et al (2016) Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol 129:453–460
Barrett D, Fish JD, Grupp S (2010) Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin N Am 57:47–66
Saha A, Aoyama K, Taylor PA et al (2013) Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 122:3062–3073
Blazar BR, Carreno BM, Panoskaltsis-Mortari A et al (2003) Blockade of programmed death-1 engagement accelerates graft-versus-host dis- ease lethality by an IFN-gamma-dependent mechanism. J Immunol 171:1272–1277
Gubin MM, Schreiber RD (2015) CANCER: the odds of immunotherapy success. Science 350:158–159
Zhang J, Walsh MF, Wu G et al (2015) Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373:2336–2346
Shlien A, Campbell BB, de Borja R et al (2015) Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet 47:257–262
Durno CA, Aronson M, Tabori U et al (2012) Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 59:652–656
Zhu X, McDowell MM, Newman WC et al (2017) Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J Neurosurg Pediatr 19:249–253
Prins RM, Soto H, Konkankit V et al (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615
Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534-542
Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697
Weber JS, Yang JC, Atkins MB et al (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33:2092–2099
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding.
Conflict of interest
All authors have no conflicts of interest.
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Rights and permissions
About this article
Cite this article
Lucchesi, M., Sardi, I., Puppo, G. et al. The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies. Cancer Chemother Pharmacol 80, 1047–1053 (2017). https://doi.org/10.1007/s00280-017-3450-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-017-3450-2